A global consensus in The Lancet has officially renamed one of the most prevalent hormonal disorders in women, the Polycystic Ovary Syndrome (PCOS) to the Polyendocrine Metabolic Ovarian Syndrome (PMOS). It is a change for more than 14 years of international research and over a decade of patient feedback and collaboration amongst medical experts from around the world. Many people were misled by the previous title \u201cPCOS\u201d as they did not necessarily have to have an ovarian cyst and the condition had a wide impact on metabolism, hormones, mental health, skin quality and cardiovascular health too. The new name is intended to enhance the diagnosis, awareness and treatment of millions of women around the world.<\/p>\n
PCOS to PMOS is being represented as a significant shift in understanding PCOS for women’s healthcare, which entails a shift in medical and social prospection of the disorder. The older term was a poorly-defined condition of the ovary mainly; the newer term, PMOS, treats the disorder as a complex endocrine and metabolic disease of the whole body, experts say. This may result in earlier diagnosis, better multidisciplinary treatment and an increase of research funds. Numerous women have reported a lack of understanding for years, with many of the signs such as insulin resistance, weight gain, anxiety, acne, and cardiovascular signs coming as a shock. The new labels should help to eliminate the stigma associated with biopolymers, and motivate all health-care delivery systems around the world to broaden their scope and patient-centered view of treatment and awareness.<\/span><\/p>\n